Dr. Hoffmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3901 Rainbow Blvd
Kansas City, KS 66160Phone+1 913-913-5000Fax+1 913-588-1280- Is this information wrong?
Summary
- Dr. Marc Hoffmann is an assistant professor of hematology at the University of Kansas Cancer Center in Kansas City, where he also serves as medical director of quality improvement. He received his medical degree from the University of Pennsylvania and hematology and oncology fellowship at MD Anderson. He specializes in hematologic oncology with interest in lymphoma and CLL.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2008 - 2011
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2008 - 2009
- Perelman School of Medicine at the University of PennsylvaniaClass of 2008
- Yale UniversityBS, 1996 - 2000
Certifications & Licensure
- MO State Medical License 2015 - 2025
- KS State Medical License 2015 - 2024
- TX State Medical License 2012 - 2017
- PA State Medical License 2008 - 2012
Awards, Honors, & Recognition
- Anne Marie Chirico Award for Excellence in Primary Care University of Pennsylvania School of Medicine, 2008
- Gamble Scholarship University of Pennsylvania School of Medicine, 2008
- Magna Cum Laude Yale University, 2000
Publications & Presentations
PubMed
- Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.William Wesson, Nausheen Ahmed, Aliya Rashid, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, Maggie Nelson, James A Davis, Mary McGann, Leyla Shune, Marc Hoffmann,...> ;European Journal of Haematology. 2024 Apr 1
- Routine consolidation of early stage primary bone lymphoma with radiation therapy does not improve outcomes.Marc S Hoffmann> ;Haematologica. 2023 Nov 16
- 8 citationsOvercoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.Marc S Hoffmann, Bradley D Hunter, Patrick W Cobb, Juan C Varela, Javier Munoz> ;Transplantation and Cellular Therapy. 2023 Jul 1
- Join now to see all
Journal Articles
- Confronting Linguistic Disparities in Health Care: Penn Language Link.Hoffmann MS, Linton JM, Shearer L, Cohen KA, Etzel NK, Context Journal
- Insulin Augmentation in a Texas Medicaid Population With Type 2 Diabetes.Lee WC, Hoffmann MS, Johnsrud M; Pashos CL, Drug Benefit Trends
Abstracts/Posters
- Dramatic response of high-grade mediastinal diffuse large B-cell lymphoma to Helicobacter pylori eradication alone.Hoffmann MS and S Gluckman, Society of General Internal Medicine Annual Meeting
- Trends in Ceftazidime and Ciprofloxacin Resistance among US Inpatient K pneumoniae and E coli Isolates.Hoffmann MS, Eber MR, Laxminarayan R, 5th Decennial International Conference on Healthcare-Associated Infections
- Hands-on Cultural Competency Training Through Student Medical Interpretation.Hoffmann MS, Marein-Efron G, Etzel NK, Larson S, Luiggi H, Association of American Medical Colleges Annual Meeting
Press Mentions
- Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudyOctober 5th, 2021
Professional Memberships
- Member
Other Languages
- Spanish, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: